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Introduction
Recombinant adeno-associated viral (AAV) vectors have met 
safety endpoints in several phase 1 gene therapy clinical tri-
als for treating Hemophilia, Alpha-1 Antitrypsin deficiency, 
and Alzheimer disease amongst other indications.1–3 Although 
vector redosing might be essential in some indications due 
to loss of gene expression observed in long term follow up 
studies,4 preclinical studies continue to show promise and 
advance with cautious optimism. One concern noted in hemo-
philia gene therapy clinical trials is the potential for vector 
dose-related hepatotoxicity in patients as evidenced by a rise 
in transaminases.2,5 Although resolvable by administration of 
anti-inflammatory steroids such as methyl prednisolone, per-
manent loss in gene expression has been observed.2 The 
dose and composition of clinical AAV vectors has been shown 
to influence these outcomes in preclinical toxicity studies.6
Concurrent with the advent of AAV vector technology, 
recent studies in animal models have demonstrated the appli-
cation of clustered, regularly interspaced, short palindromic 
repeats (CRISPR)/Cas9 technology for targeted disruption of 
genomic loci in vivo,7–10 as well as disease correction.8,11,12 
While the recombinant AAV vector platform offers a versa-
tile platform for therapeutic delivery of CRISPR/Cas9 in vivo, 
integration of the two technologies can pose unique chal-
lenges to clinical translation.
So far, over a hundred naturally occurring strains of 
AAV derived from human and animal tissues have been 
isolated.13,14 Multiple strains ranging from AAV serotypes 1–9 
and Rh.10 are under active development as gene therapy 
vectors for different clinical indications.15,16 Recent data from 
clinical gene therapy trials to treat Parkinson and Alzheimer 
disease have provided information that is critical toward con-
tinued AAV vector development.3,17 In addition, preclinical 
studies involving intravascular/intrathecal (IT) administra-
tion in mouse, canine, feline, and nonhuman primate models 
have supported the advancement of serotypes such as AAV9 
as candidates for clinical trials.18–22 Notably, AAV9 is currently 
being evaluated in phase 1 clinical trials for the treatment of 
Spinal muscular atrophy by intravascular injection and Giant 
axonal neuropathy through IT injection (Clinical trial identi-
fiers NCT02122952 and NCT02362438).
A key observation from preclinical studies is that central 
nervous system (CNS) administration of several naturally 
occurring AAV strains often results in vector sequestra-
tion within peripheral organs such as the liver and spleen 
via systemic leakage.19,22–24 In this study, we address this 
potential concern through vector design. We have previously 
demonstrated grafting of the galactose binding motif from 
AAV9 capsid, onto other AAV surfaces as a viable strategy 
to engineer AAV vectors with novel gene transfer properties. 
Specifically, the viral protein 3 amino acid residues on AAV9 
capsid required for galactose binding were used to replace 
corresponding residues on the AAV2 capsid (viral protein1 
numbering: Q464V, A467P, D469N, I470M, R471A, D472V, 
S474G, Y500F, S501A) using site-directed mutagenesis. 
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Gene therapy using recombinant adeno-associated viral (AAV) vectors is emerging as a promising approach to treat central 
nervous system disorders such as Spinal muscular atrophy, Batten, Parkinson and Alzheimer disease amongst others. A critical 
remaining challenge for central nervous system-targeted gene therapy, silencing or gene editing is to limit potential vector 
dose-related toxicity in off-target cells and organs. Here, we characterize a lab-derived AAV chimeric (AAV2g9), which displays 
favorable central nervous system attributes derived from both parental counterparts, AAV2 and AAV9. This synthetic AAV strain 
displays preferential, robust, and widespread neuronal transduction within the brain and decreased glial tropism. Importantly, 
we observed minimal systemic leakage, decreased sequestration and gene transfer in off-target organs with AAV2g9, when 
administered into the cerebrospinal fluid. A single intracranial injection of AAV2g9 vectors encoding guide RNAs targeting 
the schizophrenia risk gene MIR137 (encoding MIR137) in CRISPR/Cas9 knockin mice resulted in brain-specific gene deletion 
with no detectable events in the liver. This engineered AAV vector is a promising platform for treating neurological disorders 
through gene therapy, silencing or editing modalities.
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This resulted in rational engineering of a chimeric AAV strain 
(AAV2g9) which harbors the ability to engage either heparan 
sulfate (HS) or galactose as receptors for cell entry.25,26 Earlier 
studies employing a similar approach were used to replace 
the HS binding motif of AAV2 (585-RGNRQA-590) with the 
corresponding residues of AAV8 (585-QQNTAP-590). This 
resulted in the engineering of HS binding deficient version of 
AAV2 capsid i.e., AAV2i8. The latter heparin-binding deficient 
capsid was then used as a template toward the generation 
of chimeric AAV2i8g9 (ref. 37). In this study, we demonstrate 
exceptional CNS transduction efficiency following single 
bolus injections of AAV2g9 as validated by two routes of 
administration in neonatal and adult rodents. More impor-
tantly, we establish potentially useful attributes of AAV2g9 
for CNS-specific gene therapy applications, namely, prefer-
ential neuronal tropism, restricted CNS biodistribution and 
minimal transgene expression in off-target peripheral organs. 
Furthermore, we extend these findings to demonstrate the 
utility of AAV2g9 for targeted disruption of the MIR137 locus 
in CRISPR/Cas9 transgenic mouse.9
Results
AAV2g9 and AAV9 display similar spread and trans-
duction efficiencies in the CNS
We first carried out neonatal (P0) mouse intracerebroven-
tricular injections (ICV) comparing AAV2g9 and AAV9 vec-
tors packaging a self-complementary green fluorescent 
protein (ScGFP) cassette driven by the ubiquitous chicken β 
actin hybrid (CBh) promoter. At 2 weeks post administration 
(3.5 × 109 vector genomes (vg)/mouse), diaminobenzidine 
immunohistochemistry and confocal microscopy analysis 
of postfixed mouse brain sections revealed extensive GFP 
expression across multiple sections in the rostrocaudal axis 
of the mouse brain for both AAV strains (Figure 1a). Specifi-
cally, we observed robust transduction in the olfactory bulb, 
striatum, hippocampus, and cortical regions of the mouse 
brain. High magnification insets further demonstrate that 
AAV9 injections result in GFP expression in cells with neuro-
nal or glial morphology. On the other hand, mice injected with 
AAV2g9 show selective GFP expression in neurons. Further-
more, it is important to note that AAV2g9 injections result in 
robust GFP expression in the CNS tissue immediately sur-
rounding lateral ventricular cerebrospinal fluid (CSF) space. 
Specifically, we observed strong transduction along the hip-
pocampal boundary within the caudal sections of AAV2g9 
injected mouse brains. On a cellular level, these are mixture 
of ependymal cells and neuronal projections within corpus 
callosum and medial forebrain bundle system. This robust 
transduction was not observed due to AAV9 administrations.
To further compare cellular transduction profiles of the two 
vectors, we generated higher magnification confocal micro-
graphs of functionally relevant regions of the brain including 
the cortex, amygdala, hypothalamus, and hippocampus. Mice 
injected with AAV9 or AAV2g9 showed comparably robust 
GFP expression in these regions (Figure 1b). Additionally, 
we observed that while AAV9 treatment resulted in GFP+ 
cells with neuronal or glial morphology, AAV2g9 mediated 
GFP expression was mostly restricted to neurons. We further 
validated this observation using immune colocalization with 
the neuronal antigen marker, NeuN or glial fibrillary acid pro-
tein marker, glial fibrillary acid protein (GFAP). These results 
were further confirmed upon quantitation, which revealed 
a ~4 fold reduction in GFP+ cells with glial morphology for 
AAV2g9, but no significant differences between the two vec-
tors in neuronal populations (Figure 3a,b). Overall, these 
results suggest that AAV2g9 spreads efficiently across the 
neonatal mouse brain, while demonstrating a robust and 
neurotropic transduction profile from a single unilateral ICV 
injection.
AAV2g9 and AAV9 display different cell-type specificities 
in the CNS
We then generated AAV9 and AAV2g9 vectors packaging 
single-stranded (ss) GFP cassettes driven by the neuron-
specific human synapsin I (hSyn) or the glia-specific GFAP 
promoter. Vectors (3.5 × 109 vg/mouse) were administered in 
postnatal day 0 (P0) mice via the ICV route and postfixed 
brain tissues analyzed at 2 weeks postadministration by 
diaminobenzidine immunohistochemistry, immunostaining, 
and confocal microscopy analysis. Both AAV9 and AAV2g9 
vectors packaging transgene driven by hSyn promoter dis-
played robust transduction across multiple sections of the 
mouse brain (Figure 2a). Specifically, we observed GFP+ 
cells colocalizing with NeuN+ cells (yellow) in various regions 
including the striatum, cortex, hippocampus, amygdala, and 
hypothalamus (Figure 2b). As expected, no glial staining was 
observed for either vector supporting the potential applica-
tion of such neuron-specific promoters for CNS gene therapy 
studies.
In contrast, to hSyn promoter driven expression, we 
observed striking differences in the patterns of GFP expres-
sion mediated by AAV9 and AAV2g9 vectors packaging the 
GFAP promoter driven transgene cassette. Notably, AAV9 
injections resulted in widespread GFP expression in cells 
with glial morphology across the entire brain parenchyma in 
multiple brain sections (Figure 2c). In contrast, mice injected 
with AAV2g9 exhibit spatially restricted GFP expression 
within close proximity of the site of CSF injection (lateral ven-
tricles) or along the immediate point of contact between the 
CSF and brain parenchyma, the inner meninges. To further 
confirm these observations, we coimmunostained different 
sections of the mouse brain for GFP expression (green) with 
neuronal marker-NeuN or glial marker-GFAP (red) as before. 
High magnification confocal micrographs generated at differ-
ent brain regions show robust GFP+ expression from AAV9 
injections in GFAP+ cells, but not NeuN+ cells (Figure 2d). 
These observed patterns of transgene expression were 
further confirmed by quantitative analysis, which revealed 
~2.5-fold reduction in glial transduced area throughout the 
brain with AAV2g9 vectors under GFAP promoter activity 
(Figure 3c,d). These results demonstrate that AAV9 vectors 
packaging GFAP promoter driven expression cassettes are 
excellent candidates for glial gene transfer applications, while 
AAV2g9 appears to more neurotropic and hence suitable for 
CNS gene transfer applications targeting neuronal popula-
tions. From the AAV biology perspective, AAV2g9 appears 
to preferentially transduce neurons over glia, while this is 
patently not the case with AAV9.
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Figure 1  Comparison of transgene (GFP) expression and cellular tropisms displayed by AAV9 and AAV2g9 vectors with a 
ubiquitous promoter after ventricular (ICV) injection. Postnatal day 0 (P0) mice were injected with equal viral titers (3.5 × 109 vg) of AAV9 
or AAV2g9 packaging a ScGFP transgene driven by a ubiquitous chicken β hybrid (CBh) promoter into the left lateral ventricle. At 2 weeks 
post vector administration, the mice were sacrificed and paraformaldehyde postfixed brains were sectioned and immunostained as described 
earlier. (a) Representative images of coronal sections obtained from olfactory bulbs, lateral ventricles and hippocampi are shown. Inset images 
from whole brain sections are shown to the right of each section at higher magnification. (b) Top image panel shows higher magnification 
images of DAB staining (GFP expression) in functionally relevant regions of the mouse brain namely; somatosensory cortex (SCT), piriform 
(PCT), motor CT (MCT), dentate gyrus (DG), amygdala (AMG), hypothalamus (HTL) and hippocampal CA1, CA2 and CA3 are shown. 
Middle and bottom panels show immuno-colocalization of GFP expression (green) with neuronal marker, NeuN or glial marker, GFAP (red). 
All experiments were conducted in triplicate and representative images are shown. GFAP, glial fibrillary acid protein; DAB, diaminobenzidine; 
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HS is critical for preferential neuronal transduction by 
AAV2g9 vectors
The interaction of AAV2 vectors with HS proteoglycans is 
associated with preferential neuronal transduction in the 
immediate vicinity to site of CNS administration.27,28 Coad-
ministration of soluble heparin has been shown to block 
the ability of AAV2 to bind hep and alter transduction pro-
files in vitro and in vivo.29–31 Therefore, we compared the 
CNS transduction profiles of AAV2 and AAV2g9 to coinjec-
tions of AAV2g9 with 1 µg of soluble heparin in the neonatal 
mouse brain. Further, we generated a hep binding mutant, 
AAV2i8g9, as described in earlier studies by our lab.26 Spe-
cifically, we injected equal viral titers (3.5 × 109 vg) of AAV2, 
AAV2g9, and AAV2g9 + soluble heparin or AAV2i8g9 pack-
aging CBh-ScGFP transgene via the ICV route in P0 mice. 
As shown in Figure 4a, we observed a low level of GFP+ 
expression as evidenced by diaminobenzidine immunostain-
ing within the hippocampal sections of AAV2 injected mouse 
brains. Consistent with earlier results, AAV2g9 displayed 
robust and widespread CNS transgene expression support-
ing the notion that the gal footprint enhances transduction 
efficiency and spread. Further, we observed a decrease in 
GFP+ expression across the brain parenchyma in AAV2g9 + 
soluble heparin treated animals as well as AAV2i8g9 treated 
mouse cohorts in comparison with AAV2g9 (Figure 4b–d).
High magnification confocal micrographs of multiple 
regions of the mouse brain, namely; the somatosensory 
cortex, piriform cortex, motor cortex, dentate gyrus, amyg-
dala, and hippocampal CA1, CA2, and CA3 regions were 
then generated. As seen in the top panel of Figure 4e, we 
Figure 2 Comparison of transgene (GFP) expression and cellular tropisms displayed by AAV9 and AAV2g9 vectors with cell type-
specific promoters after ventricular (ICV) injection. Postnatal day 0 (P0) mice were injected with equal viral titers (3.5 × 109 vg) of AAV9 
or AAV2g9 packaging a single-stranded GFP (ssGFP) transgene driven by the a,b hSyn promoter or the c,d GFAP promoter into the left 
lateral ventricle. At 2 weeks post vector administration, the mice were sacrificed and paraformaldehyde postfixed brains were sectioned and 
immunostained. Diaminobenzidine (DAB) immunohistochemistry was used to detect GFP expression. (a,c) Representative images of coronal 
sections obtained from olfactory bulbs, lateral ventricles, and hippocampi are shown. Inset images from whole brain sections are shown to 
the right of each section at higher magnification. (b,d) Representative confocal images of coronal tissue sections at higher magnification. 
Top image panel shows higher magnification images of DAB staining (GFP expression) in functionally relevant regions of the mouse brain 
namely; Striatum (STR), piriform CT, Motor CT, dentate gyrus (DG), amygdala (AMG), hypothalamus (HTL) and hippocampal CA1, CA2 and 
CA3 regions are shown. Middle and bottom panels show immuno-colocalization of GFP expression (green) with neuronal marker, NeuN 
or glial marker, GFAP (red) obtained using a Zeiss CLSM 700 confocal laser scanning microscope equipped with 488, 555, and 647nm 
excitation filters. Colocalized cells are pseudocolored yellow (GFP/NeuN or GFP/GFAP overlay). All experiments were conducted in triplicate 
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observed sporadic expression in neurons and astrocytes 
in case of AAV2-injected mice. On the other hand, exten-
sive and preferential neuronal transduction was observed 
across these regions in case of AAV2g9 as observed earlier 
(Figure 4e, second row panel). In contrast, loss of hep bind-
ing, either by competitive inhibition with soluble heparin or 
with the AAV2i8g9 mutant resulted in a decreased neuronal 
transduction in multiple brain regions (third row and bottom 
row panels, Figure 4e). In addition, loss of neuronal transduc-
tion was accompanied by an increase in GFP+ cells with glial 
(astrocytic) morphology in these cohorts. Taken together, our 
observations suggest that hep binding is critical in determin-
ing the preferential neuronal tropism displayed by AAV2g9.
AAV2g9 and AAV9 display similar transduction profiles 
in adult mice after IT administration
To compare the two strains in adult mice, we carried out 
IT infusions of AAV9 or AAV2g9 packaging CBh-ScGFP 
reporter transgene into the lumbar CSF space of 8 week old 
mice. At 3 weeks postadministration of 1 × 1011 vg/mouse, we 
subjected postfixed tissues to immunohistochemical analy-
ses and confocal imaging as outlined in online methods. As 
shown in Figure 5a, IT infusions of both AAV9 and AAV2g9 
resulted in strong transgene expression in the lumbar, tho-
racic, and cervical spinal cord regions. Of note, we observed 
GFP expression in multiple gray and white matter regions of 
the spinal cord. Further, we compared cellular transduction 
profiles resulting from IT infusions of AAV9/2g9 vectors. Spe-
cifically, we focused on different regions of the adult CNS, 
namely: ventral horn, dorsal horn, intermediate gray matter 
region, ventral funiculus, lateral funiculus, ventral commis-
sure, and rubrospinal tract. As shown in Figure 5b, both 
AAV2g9 and AAV9 infused mice exhibit robust GFP expres-
sion in these regions of the spinal cord. In both AAV9 and 
AAV2g9 injected mice, we observed that the GFP+ cells 
(green) in the gray matter regions of the spinal cord (ventral 
horn, dorsal horn, and intermediate) extensively colocalized 
with NeuN+ as well as GFAP+ cells. Within the white mat-
ter regions of spinal cord (ventral funiculus, lateral funiculus, 
ventral commissure, and rubrospinal tract), the GFP+ (green) 
cells from either injection extensively colocalized with GFAP+ 
cells (Figure 5b). In addition, we observe a consistent drop 
in transduction in progressive rostral sections of the brain 
from IT administrations of AAV9 or AAV2g9 (data not shown). 
It is important to note that parameters such as vector dose, 
volume, and infusion rates will likely need to be optimized 
further to achieve widespread gene transfer in the brain fol-
lowing IT injections. Overall, these observations also under-
score the influence of route of injection on the cellular tropism 
of different AAV vectors.
AAV2g9 and AAV9 display distinct systemic biodis-
tribution and off-target transduction profiles following 
CNS administration
Having established the robustness of the rationally engi-
neered AAV2g9 strain, we compared the systemic leakage, 
vg biodistribution and gene expression profiles in periph-
eral organs resulting from ICV or IT injections of AAV9 and 
AAV2g9 in both neonatal and adult mice. At 3 days postad-
ministration, we extracted whole genomic DNA from different 
organs and determined vg copies using quantitative poly-
merase chain reaction (PCR) in different peripheral organs 
including the liver, heart, and spleen. We observed a striking 
difference between the off-target biodistribution profiles of 
AAV9 and AAV2g9 vectors following ICV or IT injections. As 
seen in Figure 6a–c, in the AAV9 injected neonatal mouse 
cohort, ~40, 30, and 3% of the viral genomes were recovered 
from the liver, heart, and spleen, respectively, in comparison 
with the brain (normalized to 100%). In contrast, AAV2g9 vg 
copy numbers ranged from ~1.4 0.7, and 0.003% in these 
peripheral organs. In the adult mouse cohort, AAV9 vg copies 
recovered in the liver, heart, and spleen were 188, 81, and 
59%, respectively in comparison with vg copies recovered 
from the spinal cord (normalized to 100%). In contrast, only 
~3, 4.5, and 10% of vg copies were recovered from these 
systemic organs in the AAV2g9-treated cohort (Figure 6e–g). 
These results suggest that unlike AAV9, AAV2g9 is sparingly 
sequestered in off-target, systemic organs following CNS 
administration.
To further corroborate the biodistribution results, we har-
vested different peripheral organs from the ICV and IT mouse 
cohorts treated with either AAV2g9 or AAV9 and subjected 
postfixed tissue to immunostaining and confocal imag-
ing analysis as outlined earlier. We observed robust GFP 
expression in the heart, liver, and spleen of both neonatal 
(ICV)  (Figure 6d) and adult (IT) (Figure 6h) mice treated 
Figure 3 Quantitative assessment of transduction following ICV 
administration of AAV9 and AAV2g9 vectors. GFP expression 
was quantified in representative hippocampal sections of the mouse 
brains treated with AAV9 or AAV2g9 vectors. Specifically, GFP+ cells 
with neuronal (a) or glial (b) morphology were counted in different 
cortical regions including the retrosplenial, posterior parietal, 
somatosensory, auditory, and piriform areas. Further, quantitative 
assessment of GFP expression following ICV administration of AAV9 
and AAV2g9 vectors driven by (c) human synapsin (hSyn) promoter 
or (d) glial fibrilary acid protein (GFAP) promoter was carried out 
using ImageJ analysis software. Specifically, the mean intensity 
calculator function was applied across multiple sections of the mouse 
brain including sections of the olfactory bulbs, lateral ventricles 
and hippocampal regions. Data is represented as mean ± SD, 
* represents P < 0.05 and n.s. indicates not statistically significant 
(P > 0.05) as determined by student’s t-test. All experiments were 
conducted in quadruplicate. AAV, adeno-associated viral; GFP, green 




























































































Brain-specific Gene Deletion with a Novel AAV Vector
Murlidharan et al.
6
with AAV9. Consistent with biodistribution data, AAV2g9 
treated mice exhibit near background levels of GFP expres-
sion in both ICV and IT cohorts. Together, these results are 
also consistent with the reduced leakage of AAV2g9 vectors 
(>100-fold) into the blood circulation that was observed in 
comparison to AAV9 vectors (Figure 7). Briefly, AAV9 vec-
tor genomes were observed in blood as early as 15 minutes 
postadministration and continued to decline over 2 days. 
These results are consistent with earlier studies reported by 
our lab and others.32,33 In contrast, AAV2g9 vector genomes 
remained near background levels with a slight increase in 
copy number observed at the 24- and 48-hour time inter-
vals. Together, our results confirm that unlike AAV9, AAV2g9 
undergoes significantly reduced systemic leakage following 
CNS administration and consequently displays low levels of 
sequestration and transgene expression in peripheral organs.
Brain-restricted deletion of MIR137 gene using AAV2g9 
in CRISPR-Cas9 knock-in mice
We have established that CNS administration of AAV2g9 
results in limited systemic exposure and efficient gene trans-
fer within the neural tissue. To further validate the potential 
advantages of the latter attributes, we generated AAV2g9 
vectors packaging two guide RNAs (gRNAs) for targeted 
disruption of the MIR137 gene in the brain. Specifically, the 
gRNAs were designed to recognize both ends of the 85bp 
pre-MIR137 region. Equal doses of AAV2g9 packaging 
MIR137gRNA or controlgRNA were administered into Cas9 
transgenic mice9 via unilateral ICV injections. At 2 weeks post 
vector administration the mice were sacrificed and organs 
were harvested. Brain and liver tissues were then subject to 
genomic DNA extraction. To evaluate gene disruption events, 
we utilized the droplet digital PCR (ddPCR) technique. Briefly, 
primers were designed to amplify 206 bp mouse genomic 
regions flanking the MIR137 target locus. Fluorescent probes 
were designed to bind MIR137gRNA target region (FAM, 
red) and an unspecific downstream locus (HEX, green). 
Successful disruption of MIR137 locus results in exclusive 
excitation of HEX probe alone (green), whereas both FAM 
and HEX probes are excited (orange) in case of no gene dis-
ruption events (Figure 8a). Next, ddPCR analysis revealed 
that the frequency of MIR137 eliminated alleles was sig-
nificantly higher (green dots) in mice that received AAV2g9- 
MIR137gRNA, as compared with AAV2g9-controlgRNA 
cohort (Figure 8c, red arrow). Correspondingly, quantita-
tive analysis of this phenomenon demonstrated a significant 
increase in mutant allele frequency within the MIR137gRNA 
injected mouse brains (Figure 8d).
Next, we examined whether AAV2g9 vector-mediated gene 
disruption events were specific to the brain. Identical ddPCR 
analysis conducted on liver DNA extracted from the same 
mouse cohorts displayed near background levels of MIR137 
elimination in the systemic organ (Figure 8e). Further quan-
titation demonstrated negligible mutant allele formation due 
to both AAV2g9-controlgRNA and AAV2g9-MIR137gRNA 
injections in the liver (Figure 8f). In addition, consistent with 
Figure 4 Heparan sulfate (HS) interactions are critical toward preferential neuronal transduction by AAV2g9 vectors. Postnatal day 
0 (P0) mice were injected with equal viral titers (3.5 × 109 vg) of AAV2, AAV2g9 or AAV2i8g9 packaging the CBh-ScGFP transgene into the 
left lateral ventricle (ICV). One cohort of mice was coinjected with 1 µg soluble heparin (Hep) per mouse as indicated. 2 weeks post vector 
administration, the mice were sacrificed and the brains were harvested and immunostained for comparing transgene (GFP) expression (black).
( a–d) Representative images of hippocampal sections from AAV2, AAV2g9, AAV2g9+Heparin or AAV2i8g9 injections have been shown. 
(e) Higher magnification images of GFP expression (black) in different regions of the mouse brain namely; somatosensory cortex (SCT), 
piriform CT, motor CT, dentate gyrus (DG), amygdala (AMG) and hippocampal CA1, CA2 and CA3 regions have been shown. The Zeiss 
CLSM 700 confocal laser scanning microscope was used to image stitched images of entire mouse brain and higher magnification images 
of individual regions. All experiments were conducted in triplicate and representative images are shown. AAV, adeno-associated viral; GFP, 
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earlier results, AAV2g9 vector genome biodistribution analy-
sis demonstrated significant enrichment of AAV genomes 
within the brain in comparison with systemic liver tissue 
(Figure 8b). Overall, our data demonstrates CNS-restricted 
gene disruption within the Cas9 transgenic mouse using ICV 
administration of engineered AAV2g9 vector.
Discussion
Recent large scale GWAS studies conducted across ~40,000 
patients led to the discovery that disruption in MIR137 gene 
function is strongly correlated with Schizophrenia disease 
occurrence.34,35 Here, we utilize this well-known gene target 
to illustrate the utility of a novel, lab-derived AAV vector for 
CNS-specific gene transfer. Since MIR137 and CAG promoter 
driven Cas9 are both expressed constitutively in brain and 
liver tissue,9,36 it is safe to assume that brain specific MIR137 
disruption relies on AAV2g9 vector design. The efficiency of 
AAV-mediated gene editing achieved in the current study is 
similar to that demonstrated earlier with the CRISPR/Cas9 
knock-in mouse model.9 However, improvements to vector 
design could further improve gene editing efficiency. More 
importantly, from the vector development perspective, these 
studies have broad implications for gene therapy, silencing 
and editing.
First, it should be noted that the CNS transduction effi-
ciency and systemic gene expression from a single ICV/IT 
dose of AAV9 is striking. Although this might not be ideal for 
certain CNS-specific indications due to the systemic leak-
age profile, AAV9 is certainly an optimal vector candidate 
for treatment of lysosomal storage disorders and other such 
diseases, which are characterized by multiorgan involvement 
in addition to the CNS. On the other hand, AAV2g9 displays 
favorable attributes for therapeutic applications targeting 
neuronal populations within the CNS. Further, the features 
displayed by the engineered AAV2g9 strain exemplify the fea-
sibility of making rational improvements to AAV vector design 
with the goal of imparting favorable biodistribution profiles. 
When combined with cell-specific elements such as the 
hSyn promoter, as established in the current study or miRNA 
targeting elements,22,23 such approaches could help restrict 
transgene expression to neuronal populations within the 
CNS and reduce systemic exposure. In addition, therapeutic 
delivery of gene editing nucleases using AAV2g9 could help 
mitigate the risk for off-target effects at the organ level.
From the AAV biology perspective, these studies pro-
vide new insights into the role of capsid-glycan interactions 
in determining CNS spread and systemic leakage. Earlier 
studies in our lab and others have demonstrated that the 
diverse cellular tropisms and biodistribution profiles of differ-
ent AAV strains is intricately linked to their glycan receptor 
binding profiles.37,38 For instance, intracranial injection of the 
HS binding strain, AAV2 shows restricted, neuronal gene 
expression.27 This preferential neuronal tropism of AAV2 
appears to correlate with the higher concentration of hepa-
ran sulfate proteoglycans on the surface of neurons com-
pared with glia.39 Accordingly, AAV2g9 retains its preferential 
neuronal tropism, likely due to its ability to bind HS within 
the CNS. Correspondingly, both competitive inhibition with 
soluble heparin coadministration and disrupting HS binding 
with loss of function capsid mutation (AAV2i8g9) resulted in 
ablated neuronal transduction in vivo. However, as a caveat 
to this neurotropic bias, the ability of AAV2 to bind HS with 
Figure 5 Comparison of transgene (GFP) expression and 
cellular tropism displayed by AAV9 and AAV2g9 vectors 
following intrathecal (IT) infusion. (a) Spinal cord sections 
showing cervical, thoracic and lumbar regions obtained from 
8 week old adult C57/BL6 male mice infused with AAV9 or AAV2g9 
packaging the CBh-ScGFP transgene (1 x 1011 vg) by lumbar 
puncture. Mice were sacrificed and the spinal cords were postfixed in 
paraformaldehyde, sectioned at 3 weeks post vector administration. 
Diaminobenzidine (DAB) immunohistochemistry was used to detect 
GFP expression. Inset images from whole spinal cord cross-sections 
are shown to the right of each section at higher magnification. 
(b) Representative confocal images of immunostained sections 
at higher magnification. GFP expression (top panel, green) in 
the ventral horn (VH), dorsal horn (DH), intermediate zone gray 
matter (INT), ventral funiculus (VF), lateral funiculus (LF), ventral 
commissure (VC) and rubrospinal tract (RT) regions is shown. 
Middle and bottom panels show immuno-colocalization of GFP 
expression (green) with neuronal marker, NeuN or glial marker, 
GFAP (red) obtained using a Zeiss CLSM 700 confocal laser 
scanning microscope equipped with 488, 555, and 647 nm excitation 
filters. Colocalized cells are pseudocolored yellow (GFP/NeuN or 
GFP/GFAP overlay). All experiments were conducted in triplicate 
and representative images are shown. AAV, adeno-associated viral; 
GFAP, glial fibrillary acid protein ; GFP, green fluorescent protein; 









































































Brain-specific Gene Deletion with a Novel AAV Vector
Murlidharan et al.
8
high affinity also restricts vector spread and the effective vol-
ume of CNS tissue transduced.28 In contrast, the galactose 
binding strain, AAV9, shows both neuronal and glial trans-
duction as well as efficient CNS spread.18,40 One possible 
explanation for the increased spread of AAV2g9 as com-
pared with AAV2 can be attributed to capsid interactions with 
proteins in the CSF that might facilitate spread and transport 
within the brain. Alternatively, while axonal transport of AAV2 
Figure 6 Comparison of systemic biodistribution and off-target transgene (GFP) expression displayed by ICV/IT injected AAV9 
and AAV2g9 vectors. (a-c) Relative percentage of vector genome (vg) copy numbers for AAV9 (dark gray bars) and AAV2g9 (light gray 
bars) in systemic organs, i.e., liver, heart, and spleen normalized to vg copy number in the brain following ICV administration in neonates. 
(d) Confocal micrographs showing GFP expression in systemic organs – liver, heart, and spleen obtained from neonatal ICV cohorts. 
(e–g) Relative percentage of vg copy numbers for AAV9 (dark gray bars) and AAV2g9 (light gray bars) in systemic organs, i.e., liver, heart, 
and spleen normalized to vg copy number in the spinal cord following IT administration in adult mice. (h) Confocal micrographs showing 
GFP expression in systemic organs – liver, heart, and spleen obtained from adult IT cohorts. The vg copy per host genome (vg/cell) was 
determined by quantitative polymerase chain reaction (PCR) of extracted DNA and normalized to the number of copies of the mouse lamin 
β2 gene. Data shown is represented as mean ± SD; Statistical significance (*P < 0.05) was established using student’s t-test. All experiments 
were conducted in quadruplicate and representative images are shown. AAV, adeno-associated viral; GFP, green fluorescent protein; ICV, 
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is exclusively restricted to the anterograde direction, AAV9 
is known to travel in both anterograde and retrograde direc-
tions to cover long distances within the neural tissue.16,21,37,40 
We acknowledge that such hypotheses warrant further evalu-
ation and such detailed studies will likely shed light on the 
mechanism(s) driving enhanced CNS spread of the dual 
glycan binding AAV2g9. Consistent with the latter attributes, 
AAV9 capsids also appear to be prone to systemic leakage 
and transduction in the liver and other organs following CNS 
administration.19,22,23 In this study, the dual glycan binding 
strain has inherited traits from both parental AAV serotypes, 
i.e., neurotropism from AAV2 and robust CNS spread and 
transduction from AAV9.
Materials and methods
Recombinant AAV vector production.  An updated triple plas-
mid transfection protocol was used to generate recombinant 
AAV vectors. The pXR2g9 and pXR2i8g9 plasmids have 
been described earlier.26 All other plasmids used for AAV pro-
duction in this study were obtained from the UNC vector core. 
Briefly, the transfection mixture contained (i) the pXR9 helper 
plasmid or pXR2g9/2i8g9 helper plasmids; (ii) the adenovi-
ral helper plasmid pXX6-80; and (iii) pTR-CBh-ScGFP, pTR-
hSyn-EGFP, pTR-GFAP-EGFP or pTR-CBA-Luc plasmids 
encoding the GFP or luciferase (Luc) reporter genes driven 
by the CBh, hSyn, GFAP or the chicken β actin (CBA) pro-
moters, flanked by inverted terminal repeats derived from the 
AAV2 genome. Vector purification was carried out using iodax-
inol gradient ultracentrifugation protocol, buffer exchange 
and concentration using vivaspin2 100 kDa molecular weight 
cut-off (MWCO) centrifugation columns (F-2731-100 Bioex-
press, Kaysville, UT). Vg titers were obtained by quantitative 
PCR (Lightcycler 480, Roche Applied Sciences, Pleasanton, 
CA) using primers designed to selectively bind AAV2 inverted 
terminal repeats (forward, 5′- AAC ATG CTA CGC AGA GAG 
GGA GTG G-3′; reverse, 5′- CAT GAG ACA AGG AAC CCC 
TAG TGA TGG AG-3′) (IDT Technologies, Ames, IA).
ICV administration. Animal experiments reported in this study 
were conducted with Balb/C or C57/Bl6 mice bred and main-
tained in accordance to NIH guideline as approved by the 
UNC Institutional Animal Care and Use Committee (IACUC). 
Postnatal day 0 (P0) Balb/c pups which were rapidly anes-
thetized on ice for 2 minutes followed by stereotaxic ICV 
injections. Specifically, AAV9 or AAV2g9 vectors packaging 
different transgenes were injected into the left lateral ventricle 
(total volume < 3 µl) using a Hamilton 700 series syringe with 
a 26s gauge needle (Sigma-Aldrich, St. Louis, MO), attached 
to a KOPF-900 small animal stereotaxic instrument (KOPF 
instruments, Tujunga, CA). All neonatal injections were per-
formed 0.5mm relative to the sagittal sinus, 2 mm rostral to 
transverse sinus and 1.5 mm deep. Following vector adminis-
tration, mice were revived under a heat lamp and rubbed in the 
bedding before being placed back with the dam. At 2 weeks 
post vector administrations (P14) the mouse brains were har-
vested, postfixed and immunostained as described below in 
detail. For coadministration of soluble heparin (generously 
provided by Dr Jian Liu, School of Pharmacy, UNC), AAV vec-
tors (3.5 × 109 vg) were mixed with 1 µg of heparin and a total 
volume of 2–3 µl administered per mouse for 30 minutes on 
ice prior to ICV injections in neonatal mice.
IT administration. AAV vectors were infused into the mouse IT 
cerebrospinal fluid space using Alzet mouse IT catheter and 
pump (Alzet, 0007743, Durect, Cupertino, CA). Briefly, the 
pumps were primed with 0.9% NaCl for ~12 hours followed 
by AAV vectors. Later 8 weeks old C57/Bl6 males were anes-
thetized with intraperitoneal injection of Avertin (1.25%, 2,2,2- 
tribromoethanol in phosphate-buffered saline) at 0.23 ml/10 g 
body weight prior to infusions. A 23 gauge needle was used 
to expose the L5–L6 intervertebral space and the osmotic 
pump was implanted and sutured under the skin. The vector 
was then infused at the rate of ~8 µl/hr for ~24 hours to infuse 
a total 1 × 1011 vg of AAV9 and AAV2g9 vectors packaging 
the CBh-ScGFP transgene. At 3 weeks post administration of 
the vectors, the mice were sacrificed, postfixed in paraformal-
dehyde, sectioned and immunostained as described below. 
Another cohort of 8 week old Balb/C mice was injected via IT 
bolus injections with AAV9 and AAV2g9 vectors as described 
elsewhere.41 Briefly, equal titers of vectors packaging the 
CBA-Luc transgene cassette (total volume 4–5 µl) was free-
hand injected into the L5 and L6 intervertebral space. The 
injections were carried out an angle of 20–30 degrees from 
spinal column using the 30G disposable needle attached to 
50 µl Luer-hub Hamilton syringe (Sigma-Aldrich).
Vector genome biodistribution and pharmacokinetic analyses. 
Cohorts of neonatal and adult mice used for biodistribution 
studies were sacrificed 3 days post vector administration via 
the ICV or IT bolus routes. The genomic DNA was extracted 
Figure 7 Comparison of blood circulation/pharmacokinetic 
profiles AAV9 and AAV2g9 vectors in adult mice post 
intrathecal (IT) administration. A 8 week old Balb/C mice were 
injected with equal viral titers (7.8 × 109 vg) of AAV9 or AAV2g9 
packaging CBA-Luc transgene via IT injections. Approximately 10 µl 
blood was collected via tail vein nicks from adult mice at 15 minutes, 
2 hours, 6 hours, 24 hours, and 48 hours post IT injection. Blood 
samples were immediately mixed with equal volume of sodium 
citrate (3.8% weight/volume) to avoid coagulation. Pharmacokinetic 
profiles of AAV9/2g9 vectors were generated using quantitative 
polymerase chain reaction (qPCR) to calculate viral genomes in the 
blood samples with primers specific to the luciferase transgene. Data 
represents mean ± SEM. * represents P < 0.05 as determined by 
student’s t-test. All experiments were conducted in quadruplicate. 
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from the tissue lysates and blood using the DNeay kit (Qia-
gen, Valencia, CA). To calculate viral genome copy numbers 
quantitative polymerase chain reaction was performed with 
primers specific to luciferase transgene 5′-AAAAGCACTCTG 
ATTGACAAATAC-3′ and 5′-CCTTCGCTTCAAAAAATGGAA 
C-3′. The vector genome copy numbers were normalized 
to mouse lamin B2 locus as the housekeeping gene using 
the primers 5′-GGACCCAAGGACTACCTCAAGGG-3′ and 
5′- AGGGCACCTCCATCTCGGAAAC-3′. The vector biodis-
tribution was represented as the ratio of vector genomes per 
cell recovered in the peripheral organs to the CNS site of 
injection (brain or the spinal cord). For pharmacokinetic stud-
ies, the vector genome copy numbers were calculated from 
total DNA isolated from 10 µl blood.
Tissue processing, immunofluorescence, and confocal 
microscopy.  Neonatal and adult mouse cohorts were sac-
rificed 2 weeks and 3 weeks post vector administrations 
respectively. The mice were overdosed with tribromoethanol 
(avertin) (0.2 ml/10 g of 1.25% solution) via the intraperito-
neal route. This was followed by transcardial perfusions of 
phosphate-buffered saline and 4% paraformaldehyde in 
Figure 8 CNS-restricted gene disruption of MIR137 within Cas9 transgenic mouse using AAV2g9. (a) Schematic representation 
of mouse MIR137 locus (mm10, chr3:118, 433, 800-118, 434, 004). Two gRNAs were designed to generate a 98 bp deletion within pre-
MIR137 region. Droplet digital PCR (ddPCR) primers were designed to amplify a 206 bp region (wild type mir-137) and shorter mutant 
(mir-137 eliminated) genomic DNA. Probes were designed to detect (i) unaltered region (HEX probe, green) and (ii) a region flanked by two 
MIR137gRNAs (FAM probe, red). (b) AAV2g9 vector genome (vg) copy numbers (per cell) within the brain (light gray bars) and liver (dark 
gray bars) tissues, 2 weeks post ICV administration in neonatal (P0) Cas9 transgenic mice. Scatter plots showing results of ddPCR on brain 
(c) and liver (e) genomic DNA from AAV2g9-controlgRNA (left) or AAV2g9-MIR137gRNA (right) injected mice. Specifically, HEX+/FAM+ 
double positive droplets (Orange) indicate wildtype alleles, while HEX+/FAM- droplets (Green; depicted by red arrow) demonstrate MIR137 
eliminated alleles. Results from all samples (n = 3 or 4) are pooled to generate these plots. (d and f) Quantitative analyses of ddPCR from 
controlgRNA (light gray bars) and MIR137gRNA (dark gray bars). Wild-type and mutant allele were predicted using a 2D dot plot as shown. 
Because the number of droplets with a fluorescent signal is low (<5%), we can assume that most of the positive droplets have one allele.43 
Graphical data represents mean ± SEM. *represents P < 0.05, n.s. indicates ‘not statistically significant’ (P > 0.05), as determined by student’s 
t-test. All experiments were conducted in triplicate. AAV, adeno-associated viral; CNS, central nervous system; ICV, intracerebroventricular 
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phosphate-buffered saline. The organs were removed and 
postfixed for 24 hour prior to sectioning. Briefly, 50 µm thick 
sections were obtained using a Leica VT 1,200S vibrating 
blade microtome (Leica Biosystems, Buffalo Grove, IL). The 
spinal cords were cryo-sectioned by UNC animal histopathol-
ogy core. The sections of mouse organs from various treat-
ments were blocked in 10% goat serum (Sigma-Aldrich) and 
1% Triton X (Sigma-Aldrich) in phosphate-buffered saline for 
1 hour. This was followed by overnight incubation with pri-
mary monoclonal antibodies at 4˚C. The primary antibodies 
utilized as a part of this study are as follows: Rabbit anti-
GFP (Life-Technologies-G10,362, 1:750) mouse anti-GFAP 
(Abcam-10,062, 1:1,000), rabbit anti-NeuN (Abcam-104,225, 
1:750), chicken anti-GFP (Abcam-13,970, 1:750). Sec-
ondary antibodies were raised in goats and conjugated to 
Alexa 488 (anti-rabbit Abcam-96,883, anti-chicken Abcam-
96,947), Alexa 594 (anti-Rabbit Abcam-96,885) or Alexa 
647 (anti-mouse Abcam-150,115). The secondary antibod-
ies were used at a standard dilution of 1:500. The immuno-
histochemical analyses of GFP expression was conducted 
using Vectastain ABC kit (Rabbit IgG PK-4001 kit, Vector bio-
labs, Burlingame, CA). We used Zeiss CLSM 700 confocal 
laser scanning microscope for imaging sections of different 
organs after immunostaining (Microscopy Services Labora-
tory, UNC). The images were stitched, pseudocolored, and 
analyzed on the Zen Black v 10.0 software.
CRISPR gRNA design. Two gRNAs were designed to detect 
98bp Pre-MIR137 flanking region and analyzed by COSMID 
(crispr.bme.gatech.edu) to check potential off-target sites.42 
Target sequencing used to make the gRNAs are following: mir-
137-g1; CGTCACCGAAGAGAGTCAG, mir-137-g3; GTAGTCG 
AGGAGAGTACCAG. For control gRNA, we used a 20 bp 
sequence, which recognizes an unspecific backbone region 
of plasmid DNA (Con-g1; GTCGACTCTAGAGGATCCAC). 
Tandem repeat of U6 promoter-target sequence-guideRNA is 
conjugated with EF1core promoter-tdTomato-P2A-PuroR and 
subcloned into the pTR vector for packaging into AAV.
Droplet digital PCR. PureLink Genomic DNA extraction kit 
(Thermo Fisher Scientific, K182,002) was used to obtain DNA 
from brain and liver tissues. Following sequences of primers 
and probes were used for the ddPCR assay. MMIR137L206d-
dPCR; GCAGCAGTGACAGCGGTAGC, MMIR137R206dd 




For ddPCR, 2× ddPCR Supermix for Probes (No dUTP; Bio-
rad, 1,863,023), the QX100 Droplet generator and reader (Bio-
rad) were employed. 10 ng genomic DNAs were subjected to 
PCR amplification by C1,000 thermal cycler (Bio-rad) with the 
following condition: 95°C 10 minutes × 1, (4°C 30 seconds, 
65°C 1 minutes) ×40, 98°C 10 minutes ×1; 2°C/sec. Obtained 
data was analyzed by the QuantaSoft software (Bio-rad).
Study approval. All neonatal and adult Balb/c or C57/Bl6 
mice used in the study were bred, maintained and utilized 
in accordance to NIH guidelines as approved by the UNC 
Institutional Animal Care and Use Committee (IACUC) (Pro-
tocol # 15–109).
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